Nadunolimab Biosimilar – Anti-IL1RAP mAb – Research Grade

Description of Nadunolimab Biosimilar - Anti-IL1RAP mAb - Research Grade

Introduction

Nadunolimab Biosimilar, also known as Anti-IL1RAP mAb, is a monoclonal antibody that has been developed as a biosimilar to the therapeutic antibody Canakinumab. Canakinumab is a human monoclonal antibody that targets interleukin-1 receptor accessory protein (IL1RAP), which is a key mediator of inflammation. Nadunolimab Biosimilar has been designed to have similar structure, activity, and therapeutic applications as Canakinumab, making it a promising candidate for treating inflammatory diseases.

Structure of Nadunolimab Biosimilar

Nadunolimab Biosimilar is a recombinant, fully humanized monoclonal antibody that has been engineered using advanced molecular techniques. It is composed of two identical heavy chains and two identical light chains, each with a molecular weight of approximately 150 kDa. The heavy chains consist of four constant domains (CH1, CH2, CH3, and CH4) and one variable domain (VH), while the light chains consist of two constant domains (CL and CL’) and one variable domain (VL). The variable domains of both the heavy and light chains are responsible for binding to IL1RAP.

Activity of Nadunolimab Biosimilar

Nadunolimab Biosimilar exerts its therapeutic effect by specifically binding to IL1RAP, which is a co-receptor for the pro-inflammatory cytokines IL-1α, IL-1β, and IL-33. IL1RAP is expressed on a variety of immune cells, including monocytes, macrophages, and dendritic cells, and is involved in the activation of the immune response. By binding to IL1RAP, Nadunolimab Biosimilar blocks the interaction between IL1RAP and its ligands, thereby inhibiting the pro-inflammatory signaling pathway and reducing the production of inflammatory cytokines.

Application of Nadunolimab Biosimilar

Nadunolimab Biosimilar has shown promising results in preclinical studies and is currently being evaluated in clinical trials for the treatment of various inflammatory diseases. The primary therapeutic target for Nadunolimab Biosimilar is rheumatoid arthritis (RA), a chronic autoimmune disorder characterized by inflammation and destruction of the joints. In a phase 2 clinical trial, Nadunolimab Biosimilar demonstrated significant efficacy in reducing disease activity and improving symptoms in patients with RA.

In addition to RA, Nadunolimab Biosimilar is also being studied for the treatment of other inflammatory conditions such as psoriasis, psoriatic arthritis, and ankylosing spondylitis. These diseases are characterized by dysregulated immune responses and elevated levels of IL-1 cytokines. By targeting IL1RAP, Nadunolimab Biosimilar has the potential to modulate the immune response and provide relief to patients suffering from these conditions.

Nadunolimab Biosimilar is also being investigated for its potential use in the prevention and treatment of cytokine release syndrome (CRS), a severe immune response that can occur in patients receiving certain cancer therapies. By inhibiting the IL1RAP signaling pathway, Nadunolimab Biosimilar may be able to prevent or reduce the severity of CRS in cancer patients.

Conclusion

In summary, Nadunolimab Biosimilar is a promising biosimilar of the therapeutic antibody Canakinumab. It has a similar structure and activity to Canakinumab, and has shown efficacy in preclinical and clinical studies for the treatment of inflammatory diseases such as RA, psoriasis, and CRS. As further research and clinical trials are conducted, Nadunolimab Biosimilar has the potential to become a valuable therapeutic option for patients with various inflammatory conditions.